摘要
Ithough renal grafts＇ survival and functioning have been improved with the introduction of cyclosporine A （CsA） into the immunosuppression treatment, its long-term results are still failing to meet treatment expectations. One of the important reasons is that the bioavailability of CsA varies largely among different patients but the use of CsA is not individualized. The human multidrug resistance gene-1 （MDR1） encodes P-glycoprotein （P-gp） that is responsible for resistance to foreign body and plays important roles in the absorption,
Ithough renal grafts＇ survival and functioning have been improved with the introduction of cyclosporine A （CsA） into the immunosuppression treatment, its long-term results are still failing to meet treatment expectations. One of the important reasons is that the bioavailability of CsA varies largely among different patients but the use of CsA is not individualized. The human multidrug resistance gene-1 （MDR1） encodes P-glycoprotein （P-gp） that is responsible for resistance to foreign body and plays important roles in the absorption,
